

NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support

06 Apr 2021 (#09)

[Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <u>www.grants.nih.gov</u> or <u>www.sun.ac.za/RDSfunding</u> (current & archive).

Confirm your intent to apply ASAP, but not later than **60 days** before the submission date. Tygerberg Campus: <u>cdevries@sun.ac.za</u> • Stellenbosch Campus <u>lizelk@sun.ac.za</u>

Important Notices

- <u>NOT-NS-21-050</u> Notice of Intent to Publish a Funding Opportunity Announcement for Joint NINDS and NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional). The NINDS and the NIMH plan to publish a re-issue of the R21 Funding Opportunity Announcement (FOA), <u>PA-18-358</u> - NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional). It is anticipated that the re-issue will be published to accommodate the June 16th standard R21 receipt date. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.
- <u>NOT-NS-21-051</u> Notice of Intent to Publish the Reissuance of RFA-NS-18-020, BRAIN Initiative: Novel Technologies and Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed). This Notice informs the research community that the NIH BRAIN Initiative intends to reissue Funding Opportunity Announcement (FOA) RFA-NS-18-020 "BRAIN Initiative: Novel Technologies and Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)." This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2021 with an expected application due date in October 2021.
- <u>NOT-NS-21-052</u> Notice of Intent to Publish the Reissuance of RFA-NS-18-019, BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed). This Notice informs the research community that the Institutes and Centers of the NIH BRAIN Initiative intend to reissue Funding Opportunity Announcement (FOA) <u>RFA-NS-18-019</u>, "BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2021 with an expected application due date in October 2021.
- <u>NOT-NS-21-055</u> Notice of Intent to Publish the Reissuance of PAR-18-422, NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) This notice informs the research community that the National Institute of Neurological Disorders and Stroke (NINDS) intends to reissue Funding Opportunity Announcement (FOA) <u>PAR-18-422</u> "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)". The FOA is expected to be published in May 2021 with an expected application due date in June 2021. This FOA will no longer utilize the U01 activity code. Instead, it will be reissued using the UG3/UH3 grant mechanism. This Notice is being published now to inform prospective applicants in advance of this modification and to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Notices of Special Interest (NOSI)

<u>NOT-DA-21-001</u> Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain. National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its

interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells. This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through September 9, 2024.

NOT-DA-21-014 Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity. The goal of this Notice of Special Interest [NOSI] is to support research that will define and validate a set(s) of molecular biomarkers and/or bio-signatures indicating the degree of loss of functional reserve, or of resilience of the host defense mechanisms in people with substance use disorders (SUDs) who acquired HIV (PWH) and are on antiretroviral therapy (ART). This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through September 8, 2024.

NOT-HD-21-024 Notice of Special Interest: Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01, R21) The purpose of this Notice of Scientific Interest (NOSI) is to continue a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). MODS is a clinical condition commonly encountered in the pediatric intensive care unit that is associated with significant morbidity and mortality. It is characterized by the failure or dysfunction of a consistent group of body organs or organ systems. It is triggered by a wide range of disease processes and clinical insults, most notably sepsis and trauma, and is frequently associated with uncontrolled inflammation. Despite its high prevalence and unfavorable outcomes, this clinical entity remains poorly understood. First described over 40 years ago, it still can only be described as a "syndrome," a constellation of symptoms, rather than as a specific pathologic entity with a distinguishable cause. The current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Applications may include any appropriate study design ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research solicited through this NOSI, outcomes will improve both in terms of the prevention and treatment of MODS in children. Applicants planning to submit an application in response to this NOSI are strongly encouraged to contact the NICHD scientific/programmatic contact(s) listed on this NOSI in advance of the application due date. This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through May 08, 2023.

NOT-MH-21-225 Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children. NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 - 12. Particularly, we are interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios. This notice applies to due dates on or after June 5, 2019 and subsequent receipt dates through September 8, 2022. Submit applications for this initiative using the following funding opportunity announcements (FOAs): <u>PA-20-185</u> - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- <u>PA-20-183</u> Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. 2021 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2021-1 Now Available

Letter of Intent: 30 days prior to the application due date

Hyperlink: <u>NOT-AI-21-045</u>

Application Due Date: 3:00 p.m. Eastern Time, May 24, 2021.

Funding Opportunity Announcement: The National Institute of Allergy and Infectious Diseases (NIAID), supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH.

2. Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33, Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: <u>RFA-AI-21-012</u>

Type: R61/R33

Type:

Application Due Date: August 04, 2021. Apply by 5:00 PM local time of applicant organization. Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages exploratory and developmental bi-phasic research. Applications are solicited to support the understanding of post-transcriptional regulation of intact and defective HIV RNA and to develop therapeutic strategies to alter RNA post-transcriptional modifications as a potential therapeutic platform for inhibiting HIV replication. Budget: NIAID intends to commit \$3.0M in FY 2022 to fund 4-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to 3 years of support for the R61 phase, and up to 2 years of support for the R33 phase.

3. Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed) Letter of Intent: 30 days prior to the application due date Hyperlink: <u>RFA-AI-21-009</u> Type: U01

Application Due Date: July 30, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages multidisciplinary teams to characterize mechanisms that impact resistance to HIV broadly neutralizing antibodies (bNAbs) and develop strategies to prevent and overcome HIV resistance to bNAbs.

Budget: NIAID intends to commit \$2,500,000 in FY 2022 to fund 2-3 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) Letter of Intent: 30 days prior to the application due date Hyperlink: PAR-21-210 Type: R01

Application Due Date: NIH standard due dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: National Institute of Mental Health (NIMH) seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R34, <u>PAR-21-211</u>.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. Scope of the proposed project should determine the project period. The maximum period is 5 years, however, most awards will be for 3-4 years.

5. Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)		
Letter of Intent: 30 days prior to the application due date	Hyperlink: <u>RFA-HG-21-006</u>	Type: R01
	RFA-HG-21-007	R21

Application Due Date: June 25, 2021; March 1, 2022; February 1, 2023. Apply by 5:00 PM local time of applicant organization. Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits R01 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant innovation in any of these and related areas would make significant contributions to the mission of National Human Genome Research Institute (<u>NHGRI</u>) and the field of genomics, including to many of NHGRI's other technology development goals.

Budget: NHGRI intends to commit \$2,000,000 in FY22, 23 and 24 to fund 2-5 R01 and R21 awards yearly from RFA-HG-21-006 and RFA-HG-21-007. The actual number of awards and amount are contingent on NIH appropriations, and the submission of a sufficient number of meritorious applications. **R01**= An applicant may request direct costs of up to \$700,000 per year. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed project should determine the project period. The maximum project period. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed research will vary from application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed research will vary from application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed research will vary from application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

6. Research on Autism Spectrum Disorders (Clinical Trial Optional)		
Letter of Intent: 30 days prior to the application due date	Hyperlink: <u>PA-21-199</u>	Type: R03
	<u>PA-21-201</u>	R01
	<u>PA-21-200</u>	R21

Application Due Date: NIH <u>standard due dates</u> Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant supports small, discrete, well-defined projects that can be completed in two years and that require limited resources. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, <u>PA-21-200</u>. Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, <u>PA-21-201</u>.

Budget: R03 = The combined budget for direct costs for the two-year project period may not exceed \$100,000. No more than \$50,000 in direct costs may be requested in any single year. **R01** = Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21** = The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

Research Development and Support Division (RDSD),	Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)	
Faculty of Medicine and Health Sciences, Stellenbosch University	Stellenbosch University	
5 th Floor, Teaching Block, Tygerberg Campus.	2038 Wilcocks Building, Ryneveld Street	
Enquiries: <i>Christa</i>	Enquiries: <i>Lizél</i>	
e: <u>cdevries@sun.ac.za</u> t: +27 21 938 9838	e: lizelk@sun.ac.za t: +27 21 808 2105	